Customize tfbm-1 Antibody

Description

Potential Confusion with Related Antibodies

The term "tfbm-1" may represent a misidentification or a niche antibody not covered in the provided sources. Below are antibodies with similar naming conventions or functional roles that may warrant consideration:

TfR1-Targeting Antibodies

Transferrin receptor 1 (TfR1/CD71) is a key target for cancer immunotherapy due to its overexpression in malignant cells. Antibodies targeting TfR1 include:

TXB4: A shark-derived single-domain antibody (VNAR) engineered to enhance brain penetration by shuttling TrkB agonist antibodies across the blood-brain barrier .
Bispecific antibodies: Fusions of anti-TfR1 domains with therapeutic payloads (e.g., TrkB agonists) for targeted drug delivery .

Antibody	Target	Mechanism	Application
TXB4	TfR1	Brain transcytosis via TfR1	Neurodegenerative disease therapy
Anti-TfR1	TfR1	Iron deprivation or ADCP/ADCC	Cancer therapy

TIF1-γ Antibodies and Dermatomyositis

Anti-TIF1-γ (TRIM33) autoantibodies are strongly associated with dermatomyositis (DM) and cancer. Key findings:

Prognostic value: Anti-TIF1-γ positivity predicts cancer development within 3 years of DM diagnosis (88% vs. 63% in negatives) .
Longitudinal dynamics: Antibody levels correlate with cancer remission; remission often coincides with DM symptom resolution .

Cohort	Anti-TIF1-γ+ Patients	Cancer Diagnosis	Antibody Levels
Swedish/DM	17/79	88% within 3 years	Higher at cancer diagnosis
Spanish/DM	19/79	88% within 3 years	Decline post-treatment

PD-1/PD-L1 Antibodies in Cancer Immunotherapy

PD-1/PD-L1 inhibitors (e.g., nivolumab, pembrolizumab) enhance T-cell responses by blocking immune checkpoint signaling. Key outcomes:

Efficacy: High response rates in melanoma, NSCLC, and RCC .
Antidrug antibodies (ADAs): Atezolizumab shows higher ADA rates (29.6%) compared to nivolumab (11.2%) .

Drug	Target	ADA Rate	Neutralizing Antibodies (nAbs)
Atezolizumab	PD-L1	29.6%	High incidence
Nivolumab	PD-1	11.2%	Moderate incidence

TGF-β Antibodies in Fibrosis and Cancer

TGF-β inhibitors neutralize all three isoforms (TGF-β1, -β2, -β3) to address fibrosis and tumor progression. Examples include:

XPA.42.681: A pan-TGF-β neutralizing antibody effective in xenograft models .
MAB240: Detects TGF-β1 in Western blots and ELISAs, with cross-reactivity to TGF-β3 .

Antibody	Target Isoforms	Neutralization	Application
XPA.42.681	TGF-β1/2/3	Full inhibition	Tumor growth suppression
MAB240	TGF-β1	Partial (TGF-β3)	Diagnostic assays

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

tfbm-1 antibody; T03F1.7 antibody; Dimethyladenosine transferase 1 antibody; mitochondrial antibody; EC 2.1.1.- antibody; Mitochondrial 12S rRNA dimethylase 1 antibody; Mitochondrial transcription factor B1 antibody; S-adenosylmethionine-6-N' antibody; N'-adenosyl(rRNA) dimethyltransferase 1 antibody

Target Names

tfbm-1

Uniprot No.

P91424

Target Background

Function

This antibody targets a probable S-adenosyl-L-methionine-dependent methyltransferase. This enzyme specifically dimethylates mitochondrial 12S rRNA at the conserved stem loop. Additionally, it is required for basal transcription of mitochondrial DNA. Notably, it stimulates transcription independently of its methyltransferase activity.

Database Links

KEGG: cel:CELE_T03F1.7

STRING: 6239.T03F1.7

Protein Families

Class I-like SAM-binding methyltransferase superfamily, rRNA adenine N(6)-methyltransferase family, KsgA subfamily

Subcellular Location

Mitochondrion.

Q&A

Here’s a structured FAQ collection for researchers working with TRAF-1 antibodies (note: "tfbm-1" is likely a typographical variation of TRAF-1, a tumor necrosis factor receptor-associated factor), based on scientific rigor and methodological focus:

Advanced Research Questions

How to resolve discrepancies in TRAF-1 expression data across studies?

Troubleshooting framework:

Variable	Potential Solution	Example
Cell type variability	Use primary human hepatocytes (PHH) for consistency	PHH showed uniform CLDN1 expression in HCV studies
Antibody lot variation	Revalidate with recombinant protein standards	TRAF-1 antibody AF3276 tested across lots
Post-translational modifications	Treat lysates with phosphatases/proteases	Observed in CLDN1 antibody validation

Can TRAF-1 antibodies distinguish between splice variants?

Experimental design:
- Design siRNA targeting specific exons (e.g., exon 2 vs. exon 4).
- Compare antibody binding in knockdown vs. wild-type cells using flow cytometry .
- Cross-reference with RNA-seq data for isoform expression .

What strategies improve TRAF-1 antibody performance in co-immunoprecipitation (Co-IP)?

Optimization steps:
- Use mild crosslinkers (e.g., DSP) to stabilize transient protein interactions.
- Include TRAF-1-binding partners (e.g., CD40) as positive controls .
- Validate with proximity ligation assays (PLA) for spatial resolution .

Data Contradiction Analysis

How to interpret conflicting TRAF-1 localization reports (cytoplasmic vs. membrane)?

Resolution workflow:
- Fixation method: Compare methanol (-20°C) vs. paraformaldehyde (4%) fixation .
- Epitope accessibility: Use epitope mapping (e.g., MUC1-CTD antibodies targeted specific 7-aa sequences ).
- Subcellular fractionation: Isolate membrane/cytosolic fractions before Western blotting .

Methodological Innovations

Can computational modeling predict TRAF-1 antibody-antigen interactions?

ADAPT platform integration:
- Use Assisted Design of Antibody and Protein Therapeutics (ADAPT) to simulate binding energy changes (e.g., ΔG) .
- Validate predictions with alanine scanning mutagenesis .

Table: Key TRAF-1 Antibody Validation Parameters

Parameter	Optimal Value	Supporting Study
Western blot dilution	0.5 µg/mL in 5% nonfat milk	Raji/Ramos cell validation
IHC incubation time	Overnight at 4°C	CLDN1 antibody protocols
Flow cytometry buffer	PBS + 1% FBS + 0.1% sodium azide	TRBC1 staining optimization

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

tfbm-1 Antibody